- Home
- INO vs OVID Comparison
INO vs OVID Comparison
Compare INO & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INO | OVID |
|---|---|---|
| Founded | 1979 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.9M | 117.5M |
| IPO Year | 1999 | 2017 |
Fundamental Metrics
Financial Performance| Metric | INO | OVID |
|---|---|---|
| Price | $1.75 | $1.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $9.00 | $3.40 |
| AVG Volume (30 Days) | 844.7K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.14 | 3.90 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $42,220,086.00 | $566,000.00 |
| Revenue This Year | N/A | $1,077.56 |
| Revenue Next Year | $23,060.18 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.37 | N/A |
| 52 Week Low | $1.30 | $0.24 |
| 52 Week High | $2.86 | $2.01 |
Technical Indicators
Market Signals| Indicator | INO | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 52.38 | 68.14 |
| Support Level | $1.72 | $1.43 |
| Resistance Level | $1.78 | $2.01 |
| Average True Range (ATR) | 0.10 | 0.11 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 40.13 | 87.92 |
Price Performance
Historical ComparisonAbout INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.